Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;14(4):889-895.
doi: 10.1007/s40121-025-01120-7. Epub 2025 Mar 11.

It's Here, It's There, There's Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis

Jacob M Keck  1 , Ryan K Dare  2 , Mitchell B Jenkins  2 , Juan C Rico  2 , Luke Grisham  2 , Jennifer McDonald  3 , Alina Viteri  3 , Robert W Bradsher  2
Affiliations

It's Here, It's There, There's Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis

Jacob M Keck et al. Infect Dis Ther. 2025 Apr.

Abstract

Rezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream. Herein, three patient cases are presented from an academic medical center. Infectious processes presented include drug-resistant mucosal candidiasis, prosthetic joint infection, and candidemia involving Candida auris. In all three cases, patients received rezafungin. Clinical response was demonstrated in all patients as was tolerability of rezafungin. Together these cases provide further evidence for the use of rezafungin, including its use for treatment of invasive infections other than candidemia.

Keywords: Candida auris; Candidemia; Mucosal candidiasis; Prosthetic joint infection (PJI); Rezafungin.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of Interest: Jacob Myles Keck is a consultant and speaker representative of AbbVie. Ryan Keith Dare has nothing to disclose. Mitchell Bruce Jenkins has nothing to disclose. Juan Carlos Rico has nothing to disclose. Luke Grisham has nothing to disclose. Jennifer McDonald has nothing to disclose. Alina Viteri has nothing to disclose. Robert Wilder Bradsher has nothing to disclose. Ethical Approval: This article does not contain any new studies with human participants or animals performed by any of the authors.

References

    1. Barantsevich N, Barantsevich E. Diagnosis and treatment of invasive candidiasis. Antibiotics (Basel). 2022;11:718. - PMC - PubMed
    1. Soriano A, Honore PM, Puerta-Alcalde P, et al. Invasive candidiasis: current clinical challenges and unmet needs in adult populations. J Antimicrob Chemother. 2023;78:1569–85. - PMC - PubMed
    1. Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother. 2018;73:i4–13. - PMC - PubMed
    1. Lass-Flörl C, Kanj SS, Govender NP, Thompson GR, Ostrosky-Zeichner L, Govrins MA. Invasive candidiasis. Nat Rev Dis Primers. 2024;10:20. - PubMed
    1. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62:e1–50. - PMC - PubMed

LinkOut - more resources